Antibacterial Activity of a Natural Clay Mineral against Burkholderia cepacia Complex and Other Bacterial Pathogens Isolated from People with Cystic Fibrosis

• Published in: Microorganisms (Basel) 2023-01, Vol.11 (1), p.150
• Main Authors: Behroozian, Shekooh, Zlosnik, James E A, Xu, Wanjing, Li, Loretta Y, Davies, Julian E
• Format: Article
• Language: English
• Subjects: Antibacterial activity; Antibiotics; Antimicrobial agents; Antimicrobial resistance; Asymptomatic; Bacteria; Bacterial diseases; Bacterial infections; Bronchopulmonary infection; Burkholderia cepacia; Burkholderia cepacia complex (Bcc); Clay; Clay minerals; Clinical isolates; Cystic fibrosis; Drug resistance; Gram-negative bacteria; Hydration; Infections; Mineralogy; Minerals; Mortality; Multidrug resistance; natural clay mineral; Pathogens; Patients; Pseudomonas aeruginosa; Skin; Stenotrophomonas maltophilia; Transplants & implants; Ulcers
• ISSN: 2076-2607; 2076-2607
• DOI: 10.3390/microorganisms11010150

There is an impending crisis in healthcare brought about by a new era of untreatable infections caused by bacteria resistant to all available antibiotics. Thus, there is an urgent need to identify novel antimicrobial agents to counter the continuing threat posed by formerly treatable infections. We previously reported that a natural mineral clay known as Kisameet clay (KC) is a potent inhibitor of the organisms responsible for acute infections. Chronic bacterial infections present another major challenge to treatment by antimicrobials, due to their prolonged nature, which results in repeated exposure to antibiotics and a constant selection for antimicrobial resistance. A prime example is bacteria belonging to the complex (Bcc), which particularly causes some of the most serious chronic lung infections in patients with cystic fibrosis (CF) associated with unpredictable clinical outcomes, poor prognosis, and high mortality rates. Eradication of these organisms from CF patients with limited effective antimicrobial options is a major challenge. Novel therapeutic approaches are urgently required. Here, we report the in vitro antibacterial activity of KC aqueous suspensions (1-10% / ) and its aqueous extract (L100) against a collection of extensively and multi-drug resistant clinical isolates of Bcc, , and isolated from patients with CF. These findings present a potential novel therapy for further investigation in the clinic.